Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines.
Yury Valdes-BalbinDarielys Santana-MederosFrançoise PaquetSonsire FernandezYanet ClimentFabrizio ChiodoLaura RodríguezBelinda Sanchez RamirezKalet LeonTays HernandezLila Castellanos-SerraRaine GarridoGuang-Wu ChenDagmar Garcia-RiveraDaniel G RiveraVicente Verez BencomoPublished in: ACS central science (2021)
The development of recombinant COVID-19 vaccines has resulted from scientific progress made at an unprecedented speed during 2020. The recombinant spike glycoprotein monomer, its trimer, and its recombinant receptor-binding domain (RBD) induce a potent anti-RBD neutralizing antibody response in animals. In COVID-19 convalescent sera, there is a good correlation between the antibody response and potent neutralization. In this review, we summarize with a critical view the molecular aspects associated with the interaction of SARS-CoV-2 RBD with its receptor in human cells, the angiotensin-converting enzyme 2 (ACE2), the epitopes involved in the neutralizing activity, and the impact of virus mutations thereof. Recent trends in RBD-based vaccines are analyzed, providing detailed insights into the role of antigen display and multivalence in the immune response of vaccines under development.
Keyphrases
- sars cov
- angiotensin converting enzyme
- respiratory syndrome coronavirus
- angiotensin ii
- immune response
- coronavirus disease
- binding protein
- cell free
- dengue virus
- anti inflammatory
- dendritic cells
- high resolution
- single molecule
- toll like receptor
- transcription factor
- dna binding
- inflammatory response
- molecularly imprinted
- aedes aegypti